Lung Cancer: Targeted Therapy in 2025
Lung cancer treatment has changed in the last twenty years since the discovery of EGFR mutations. In this article, we will review the current state of the art for non-small cell lung cancer (NSCLC) actionable genomic alterations (AGA). AGAs are mostly found in lung adenocarcinomas, a subtype of non-...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/3/146 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850089667821568000 |
|---|---|
| author | Nicole Bouchard Nathalie Daaboul |
| author_facet | Nicole Bouchard Nathalie Daaboul |
| author_sort | Nicole Bouchard |
| collection | DOAJ |
| description | Lung cancer treatment has changed in the last twenty years since the discovery of EGFR mutations. In this article, we will review the current state of the art for non-small cell lung cancer (NSCLC) actionable genomic alterations (AGA). AGAs are mostly found in lung adenocarcinomas, a subtype of non-small cell lung cancers. We will focus on the current treatment for EGFR mutations, ALK fusions, ROS1 fusions, BRAF V600E mutations, MET exon 14-skipping mutations, RET fusions, KRAS G12C mutations, ERBB2 mutations (also called HER2 mutations), and NTRK fusions. We will also touch on the key toxicities associated with these medications. Treatments are mostly available for the metastatic stage, but we will also discuss adjuvant therapy for EGFR mutations and ALK fusions, as well as stage III post-chemoradiotherapy treatment for EGFR lung cancer. |
| format | Article |
| id | doaj-art-ed8312aea0174debb59bc7eb7333a86c |
| institution | DOAJ |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-ed8312aea0174debb59bc7eb7333a86c2025-08-20T02:42:42ZengMDPI AGCurrent Oncology1198-00521718-77292025-03-0132314610.3390/curroncol32030146Lung Cancer: Targeted Therapy in 2025Nicole Bouchard0Nathalie Daaboul1Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, CanadaCentre Intégré de Cancérologie de la Montérégie, Université de Sherbrooke, Longueuil, QC J4V 2H1, CanadaLung cancer treatment has changed in the last twenty years since the discovery of EGFR mutations. In this article, we will review the current state of the art for non-small cell lung cancer (NSCLC) actionable genomic alterations (AGA). AGAs are mostly found in lung adenocarcinomas, a subtype of non-small cell lung cancers. We will focus on the current treatment for EGFR mutations, ALK fusions, ROS1 fusions, BRAF V600E mutations, MET exon 14-skipping mutations, RET fusions, KRAS G12C mutations, ERBB2 mutations (also called HER2 mutations), and NTRK fusions. We will also touch on the key toxicities associated with these medications. Treatments are mostly available for the metastatic stage, but we will also discuss adjuvant therapy for EGFR mutations and ALK fusions, as well as stage III post-chemoradiotherapy treatment for EGFR lung cancer.https://www.mdpi.com/1718-7729/32/3/146lung cancermolecular testingtargeted therapy |
| spellingShingle | Nicole Bouchard Nathalie Daaboul Lung Cancer: Targeted Therapy in 2025 Current Oncology lung cancer molecular testing targeted therapy |
| title | Lung Cancer: Targeted Therapy in 2025 |
| title_full | Lung Cancer: Targeted Therapy in 2025 |
| title_fullStr | Lung Cancer: Targeted Therapy in 2025 |
| title_full_unstemmed | Lung Cancer: Targeted Therapy in 2025 |
| title_short | Lung Cancer: Targeted Therapy in 2025 |
| title_sort | lung cancer targeted therapy in 2025 |
| topic | lung cancer molecular testing targeted therapy |
| url | https://www.mdpi.com/1718-7729/32/3/146 |
| work_keys_str_mv | AT nicolebouchard lungcancertargetedtherapyin2025 AT nathaliedaaboul lungcancertargetedtherapyin2025 |